SCOPUS 정보 검색 플랫폼

Gut

Volumn 62, Issue 5, 2013, Pages 660-661

Systemic treatment of advanced pancreatic cancer-step by step progress

(1) Seufferlein, Thomas a

a UNIVERSITY OF ULM (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; CAPECITABINE; ERLOTINIB; FLUOROPYRIMIDINE DERIVATIVE; FLUOROURACIL; GEMCITABINE; IRINOTECAN; OXALIPLATIN;

ADVANCED CANCER; CANCER COMBINATION CHEMOTHERAPY; CANCER PROGNOSIS; CANCER SURVIVAL; DOSE RESPONSE; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG ERUPTION; DRUG SAFETY; DRUG TREATMENT FAILURE; HUMAN; NOTE; ONCOGENE K RAS; OVERALL SURVIVAL; PANCREAS CANCER; PRIORITY JOURNAL; SALVAGE THERAPY; SYSTEMIC THERAPY; TREATMENT OUTCOME;

EID: 85027917929 PISSN: 00175749 EISSN: 14683288 Source Type: Journal
DOI: 10.1136/gutjnl-2012-303129 Document Type: Note

Times cited : (2)

References (5)

1
- 34249933404
- Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: A phase III trial of the National Cancer Institute of Canada Clinical Trials Group
- DOI 10.1200/JCO.2006.07.9525
- Moore MJ, Goldstein D, Hamm J, et al. Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer. A phase III trial of the National Cancer Institute of Canada Clinical trials group. J Clin Oncol 2007;25:1960-6. (Pubitemid 46972777)
- (2007) Journal of Clinical Oncology , vol.25 , Issue.15 , pp. 1960-1966
- Moore, M.J.¹ Goldstein, D.² Hamm, J.³ Figer, A.⁴ Hecht, J.R.⁵ Gallinger, S.⁶ Au, H.J.⁷ Murawa, P.⁸ Walde, D.⁹ Wolff, R.A.¹⁰ Campos, D.¹¹ Lim, R.¹² Ding, K.¹³ Clark, G.¹⁴ Voskoglou-Nomikos, T.¹⁵ Ptasynski, M.¹⁶ Parulekar, W.¹⁷

2
- 79955921754
- FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer
- Conroy T, Desseigne F, Ychou M, et al. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med 2011;364:1817-25.
- (2011) N Engl J Med , vol.364 , pp. 25
- Conroy, T.¹ Desseigne, F.² Ychou, M.³

3
- 84875861296
- Gemcitabine Plus Erlotinib Followed By Capecitabine Versus Capecitabine Plus Erlotinib Followed By Gemcitabine In Advanced Pancreatic Cancer: Final Results Of A Randomised Phase 3 Trial Of The Arbeitsgemeinschaft Internistische Onkologie' (AIO-PK0104)
- Heinemann V, Vehling-Kaiser U, Waldschmidt D, et al. Gemcitabine plus erlotinib followed by capecitabine versus capecitabine plus erlotinib followed by gemcitabine in advanced pancreatic cancer: Final results of a randomised phase 3 trial of the 'Arbeitsgemeinschaft Internistische Onkologie' (AIO-PK0104). Gut 2013;62:751-9.
- (2013) Gut , vol.62 , pp. 751-759
- Heinemann, V.¹ Vehling-Kaiser, U.² Waldschmidt, D.³

4
- 79960019683
- Best supportive care (BSC) versus oxaliplatin, folinic acid and 5-fluorouracil (OFF) plus BSC in patients for second-line advanced pancreatic cancer: A phase III-study from the German CONKO-study group
- Pelzer U, Schwaner I, Stieler J, et al. Best supportive care (BSC) versus oxaliplatin, folinic acid and 5-fluorouracil (OFF) plus BSC in patients for second-line advanced pancreatic cancer: a phase III-study from the German CONKO-study group. Eur J Cancer 2011;47:1676-81.
- (2011) Eur J Cancer , vol.47 , pp. 1676-1681
- Pelzer, U.¹ Schwaner, I.² Stieler, J.³

5
- 78650095716
- Molecular predictors of outcome in a phase 3 study of gemcitabine and erlotinib therapy in patients with advanced pancreatic cancer: National Cancer Institute of Canada Clinical Trials Group Study PA.3
- Da Cunha Santos G, Dhani N, Tu D, et al. Molecular predictors of outcome in a phase 3 study of gemcitabine and erlotinib therapy in patients with advanced pancreatic cancer: National Cancer Institute of Canada Clinical Trials Group Study PA.3. Cancer 2010;116:5599-607.
- (2010) Cancer , vol.116 , pp. 5599-5607
- Da Cunha Santos, G.¹ Dhani, N.² Tu, D.³

* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.